Tandem Diabetes Care, Inc. (TNDM): what the price assumes

boothcheck covers Tandem Diabetes Care, Inc. (TNDM) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-07-11.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/TNDM

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The price sits below what even a 5%/yr revenue decline would warrant; the inversion reports a bound, not a solved growth path.

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 8.7% cost of capital with 4% terminal growth over a 5-year stage, holding a 21.5% terminal operating margin (53.8% gross margin x the 40% mature-conversion prior).

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is justified by relative-multiple; asset-based land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.1%); the inversion above states its own rate.

Per-Model Detail (n=3)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

• Tandem runs a two-pump portfolio, the t:slim X2 and the smaller Mobi, both on its Control-IQ+ automation software now cleared for adults with type 2 diabetes; the FY2025 10-K describes it plainly: "The Company offers an insulin pump portfolio, which includes both the t:slim X2 and the Tandem Mobi. Both pumps feature Control-IQ+ technology", and supplies rather than hardware make up 54% of sales.
• At $15.39 (July 10, 2026) the market pays about 1.2x revenue for a business that still loses money on operations, so the bet rests on management converting a 55% gross margin into real operating profit; the 10-K is blunt that "We operate in a very competitive industry".
• Watch the August 6, 2026 second-quarter print against reaffirmed full-year guidance of $1.065 to $1.085 billion in sales and a gross margin path toward roughly 60% by the fourth quarter.

Bull Case

Follow where the cash goes. Tandem pays no dividend and buys back no stock; every dollar it raises or generates is pointed at product and runway. The FY2025 10-K details the balance-sheet housekeeping behind that posture: the company used "the net proceeds to repurchase approximately $246.7 million in aggregate principal amount of its Convertible Senior Notes Due 2025 (the 2025 Notes) concurrently with the pricing of the 2029 Notes", pushing its convertible maturity wall out to 2029 while it finishes the harder work of making the income statement turn. That is management telling you where it sees value: not in financial engineering, but in buying time for a margin transformation that is visibly underway. First-quarter gross margin reached about 55%, up nearly five points from a year earlier, and guidance calls for 56% to 57% for the year, scaling toward 60% by the fourth quarter.

The revenue base that transformation sits on is stickier than a hardware company's. Supplies and other recurring lines are 54% of sales, and the filing explains the annuity mechanics: "revenue related to the complementary products is deferred and recognized over a four-year period", matching the pump's warranty life. The replacement engine is structural too: "Insulin pumps in the U.S. have generally been reimbursed by third-party insurance carriers, government plans or healthcare systems through a medical benefit, subject to a four-year reimbursement cycle", which means an installed base earned once keeps generating purchase decisions on a schedule. The first quarter showed the machine working: more than 29,000 pumps shipped worldwide and sales of $247.2 million, up 7% in the U.S..

The addressable market is also widening just as the model improves. Control-IQ+ launched commercially for adults with type 2 diabetes in March 2025, a population several times the type 1 base, and the CE mark extension in Europe covers type 2 adults and use during pregnancy, while t:slim X2 compatibility with Abbott's FreeStyle Libre 3 Plus sensor opened five international markets. Here is the quiet arithmetic under the bull case: at roughly 1.2x revenue, today's price would be consistent with a business whose sales shrink every year. Reaffirmed guidance says sales are growing. If the gross margin path holds and any of the type 2 opportunity lands, the market is currently paying a declining-business price for a growing one.

Bear Case

The advantage that built Tandem is the one being chipped away. For years the moat was software: Control-IQ made an ordinary pump smart, and that algorithm edge won share from bigger rivals. Automated insulin delivery is now the whole category's roadmap, not Tandem's alone. Insulet's own 10-K names Tandem alongside "emerging companies like Beta Bionics Inc." in its competitive set and notes that competitors may develop superior products, while Dexcom's filing describes Abbott and Medtronic pressing the same integrated-ecosystem race. Tandem's 10-K concedes the ground candidly: "We operate in a very competitive industry", and its pumps depend on partner CGM sensors staying competitive against rivals' tightly coupled systems. When everyone has automation, the differentiator drifts toward form factor, channel, and price, and Insulet's tubeless Omnipod already owns the form-factor argument with much of the new-patient market.

The category itself faces a slow leak. The 10-K flags that since 2023 the adoption of GLP-1 drugs in diabetes, and even the perception of treatment advancements, "could result in delayed purchases or a decline in market share". Layer on reimbursement fragility, where the same filing warns that if payors deny coverage or cut payment levels "we may be unable to sell our products on a profitable basis", and the four-year replacement cycle that the bull case reads as an annuity becomes a recurring competitive shootout: every renewal is a fresh chance for a patient to walk to Omnipod, a Beta Bionics iLet, or off pumps entirely.

Then there is what the price already requires. Cheap-looking at 1.2x sales, the valuation still embeds a future in which this company earns something like a 21.5% operating margin on its 53.8% gross margin; the trailing operating margin is roughly negative 8%. That gap between demonstrated and required is the whole bear case in one line: the transformation has to happen, not merely continue. Meanwhile the balance sheet leaves modest room for stumbles. Gross debt of $642 million sits against $570 million of cash and liquid assets, interest coverage is negative while operating income is negative, and the share count has crept up about 1.7% a year over four years. Book value is $1.94 a share, so the asset-value lens sits far beneath the price; if the margin story stalls, there is not much floor under the equity.

Valuation

At about 1.2x revenue, today's $15.39 price (July 10, 2026) is so low relative to sales that it sits below what even a business shrinking 5% a year would warrant, provided that business eventually converts its 53.8% gross margin into an operating margin around 21.5%. That conditional is the entire bet. Tandem's trailing operating margin is about negative 8% on the EDGAR twelve-month basis (a separate record-basis operating income figure diverges from it; the two are different measurement bases, and the negative EDGAR read is the one used here). The market is not paying for growth. It is paying, skeptically, for conversion: the price assumes the margin transformation either happens or the business fades, and it leans toward fade.

The valuation methods split in a way that maps that skepticism. The earnings-power and cash-flow lenses produce no read at all: earnings and free cash flow are negative, and projection-based approaches are unreliable for a company with sustained losses and negative retained earnings. What remains disagrees violently. The peer-multiple lens lands far above the price, with the healthcare-sector sales multiple implying the price sits at roughly a quarter of where a typical sector name at these revenues would trade. The asset-value lens lands far below, with the price at about eight times book-value-based reads on $1.94 of book value per share. Between a near-asset-floor and a healthy-medtech multiple, the market has parked TNDM close to the pessimistic end. That spread, not any single number, is the finding.

The mix and the balance sheet frame the downside. Revenue is 46% pumps and 54% supplies and other, with part of the supplies stream deferred and recognized over the four-year warranty life of the pump, which smooths the base the margin work builds on. The company is not burning cash, liquid assets of $570 million nearly cover $642 million of gross debt (net debt about $72 million), and the convertible maturity wall was pushed to 2029 when the company repurchased approximately $246.7 million of its 2025 notes. The costs of that runway are a negative interest-coverage read while operating income stays negative and a share count drifting up about 1.7% a year. Full-year guidance of $1.065 to $1.085 billion in sales with gross margin scaling toward 60% by the fourth quarter is the yardstick the conversion thesis gets measured against next.

Catalysts

The first quarter, reported in early May 2026, was the proof-of-concept print for the margin story: record first-quarter worldwide sales of $247.2 million, up 7% in the U.S. and 3% internationally, more than 29,000 pumps shipped, and gross margin of about 55%, up nearly five points year over year. Management reaffirmed full-year 2026 guidance of $1.065 to $1.085 billion in worldwide sales, including $730 to $745 million in the U.S., with gross margin of 56% to 57% for the year and roughly 60% expected by the fourth quarter.

The street has started repositioning around the channel shift. Wells Fargo upgraded the stock on May 31, 2026, calling the move toward a pharmacy-benefit distribution model transformational for the pump economics, while Deutsche Bank initiated coverage at Hold on June 9, 2026. The disagreement between those two calls is effectively a bet on how fast pharmacy-channel access and type 2 adoption convert into revenue.

The next dated event is the second-quarter report on August 6, 2026. The items worth watching inside it: whether gross margin stays on the path toward the 60% fourth-quarter target, pump shipment momentum as Control-IQ+ for type 2 adults matures past its first year, and international contribution as t:slim X2 compatibility with Abbott's FreeStyle Libre 3 Plus sensor rolls through its five launch markets.

Peer Cohorts (Per Segment, With Filing Citations)

Insulin Pumps and Supplies (reported)

• PODD (INSULET CORPORATION)
• FY2025 10-K: …from MDI. Our distributors have also implemented virtual training programs. Customer Support We seek to provide our customers with high quality customer support, from product ordering to insurance investigation, order fulfillment, and ongoing support. Our customer support systems are integrated with our sales,…
• FY2025 10-K: Care Inc., as well as emerging companies like Beta Bionics Inc. Our competitors may develop products in the future that are superior to ours which would inhibit our ability to compete effectively. In addition to the insulin pump competitors, we compete with companies that provide products and supplies for MDI therapy.…
• DXCM (DEXCOM, INC.)
• FY2025 10-K: …new product introductions and other market activities of industry participants. In selling our current CGM systems, we compete directly with the Diabetes Care division of Abbott Laboratories; Medtronic plc's Diabetes Group (which implemented a spinoff of its diabetes business into a separate company called MiniMed);…
• FY2025 10-K: …insulin delivery devices. We are also aware of companies outside the traditional medical device sector that are attempting to develop competitive products and services, including for the general health and wellness, or population health space. Some of the companies developing or marketing competing devices are large…
• INSP (Inspire Medical Systems, Inc.)
• FY2025 10-K: …0001609550 false 2025 FY P3Y http://fasb.org/us-gaap/2025#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2025#AccruedLiabilitiesCurrent P3Y P1Y iso4217:USD xbrli:shares iso4217:USD xbrli:shares insp:custodian insp:healthcare_system insp:security utr:sqft insp:renewal_option xbrli:pure insp:segment insp:claim…
• FY2025 10-K: …in demand could have a significant impact on the carrying value of our inventories and reported operating results. Likewise, the timing of FDA approval of a next generation product, if granted, and the associated commercial launch, could have a significant impact on the carrying value of the inventory of our previous…
• ATRC (AtriCure, Inc.)
• FY2025 10-K: …approvals for us to use, creating lost sterilization capacity and delays; • our suppliers manufacture products for a range of customers, and fluctuations in demand for the products those suppliers manufacture for others may affect their ability to deliver components to us in a timely manner; and • our suppliers may…
• FY2025 10-K: …us-gaap:SalesRevenueNetMember 2024-01-01 2024-12-31 0001323885 atrc:MedicalDevicesMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-12-31 0001323885 atrc:MedicalDevicesMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2025-01-01 2025-12-31…
• IRTC (iRhythm Holdings, Inc.)
• FY2025 10-K: …to applicable requirements relating to the environment, waste management, and health and safety matters, including measures relating to the release, use, storage, treatment, transportation, discharge, disposal, sale, labeling, collection, recycling, treatment, and remediation of hazardous substances. We purchase…
• FY2025 10-K: …us-gaap:SalesRevenueNetMember 2023-01-01 2023-12-31 0001388658 irtc:CentersForMedicareAndMedicaidMember 2025-01-01 2025-12-31 0001388658 irtc:CentersForMedicareAndMedicaidMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember 2025-01-01 2025-12-31 0001388658…
• MASI (MASIMO CORP)
• FY2025 10-K: …noninvasive portable hemoglobin spot-check monitoring. 9 Table of Contents Patient Monitoring and Connectivity Platform Radius VSM ® is a wearable vital signs monitoring platform that includes three single-use sensors: a chest patch, a blood pressure cuff, and a finger sensor. As an on-demand, connected, continuous…
• FY2025 10-K: …partners; • access to hospitals which are members of GPO and OEM partners; and • patent protection. Market Demand We currently sell our products directly to hospitals and various distributors in the U.S. and around the world, including Europe, the Middle East and Asia Pacific, through our direct sales force. Our…
• ICUI (ICU MEDICAL INC/DE)
• FY2025 10-K: …reliability, patent protection, ease of use and the pricing of our products, in addition to the access to distribution channels. We encounter significant competition in this market both from global, large, established medical device manufacturers and from smaller companies. We compete with products and systems…
• FY2025 10-K: …uncertainties and assumptions, including without limitation, the following: • our failure to compete successfully with our competitors and maintain market share; • significant decline in demand for our products; • our inability to fund substantial investment in product development and recover such investment through…
• HAE (HAEMONETICS CORPORATION)
• FY2025 10-K: …collection and manufacturing processes. As a result, we aim to design equipment that is durable, dependable, and easy to use and to provide comprehensive training and support to help our customers optimize their plasma collections. Today, nearly all source plasma collections worldwide are performed using automated…
• FY2025 10-K: …Philips pose challenges and opportunities in the coronary physiology segment, each offering their own technologies and solutions. There are not currently competing, commercially available TAVR guidewires that are indicated to deliver both hemodynamic measurement and LV pacing for TAVR procedures. Esophageal…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.